<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
The medical community has not been entirely convinced of the U.S. FDA’s decision to approve Biogen Inc’s (NASDAQ: BIIB) Aduhelm drug to treat Alzheimer’s last month. Some health insurers also declined coverage for Aduhelm The latest blow to the biotech firm came late on Thursday when Providence, Mount Sinai Health System, and the Cleveland Clinic […] The post Here’s why three hospitals are refusing to treat patients with Biogen’s new Alzheimer’s drug appeared first on Invezz.
...read full article on Invezz
